CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The BILCAP study established capecitabine as the adjuvant standard of care for patients after curatively resected biliary tract cancer (BTC). This publication presents the long-term data of that study. In the intention-to-treat analysis, the median OS was 49.6 months in the capecitabine group compared with 36.1 months in the observation group.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
